142 related articles for article (PubMed ID: 35902716)
21. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
[TBL] [Abstract][Full Text] [Related]
22. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
Venderbos LD; van den Bergh RC; Roobol MJ; Schröder FH; Essink-Bot ML; Bangma CH; Steyerberg EW; Korfage IJ
Psychooncology; 2015 Mar; 24(3):348-54. PubMed ID: 25138075
[TBL] [Abstract][Full Text] [Related]
23. Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable-risk prostate cancer patients: A 9-month longitudinal study.
Ruane-McAteer E; Porter S; O'Sullivan J; Dempster M; Prue G
Psychooncology; 2019 Aug; 28(8):1743-1752. PubMed ID: 31243872
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.
Stattin P; Holmberg E; Johansson JE; Holmberg L; Adolfsson J; Hugosson J;
J Natl Cancer Inst; 2010 Jul; 102(13):950-8. PubMed ID: 20562373
[TBL] [Abstract][Full Text] [Related]
25. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
26. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy versus watchful waiting for prostate cancer.
Hegarty J; Beirne PV; Walsh E; Comber H; Fitzgerald T; Wallace Kazer M
Cochrane Database Syst Rev; 2010 Nov; (11):CD006590. PubMed ID: 21069689
[TBL] [Abstract][Full Text] [Related]
28. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.
Abdel-Rahman O
Clin Transl Oncol; 2019 Dec; 21(12):1673-1679. PubMed ID: 30929179
[TBL] [Abstract][Full Text] [Related]
30. Mental health outcomes in elderly men with prostate cancer.
Ravi P; Karakiewicz PI; Roghmann F; Gandaglia G; Choueiri TK; Menon M; McKay RR; Nguyen PL; Sammon JD; Sukumar S; Varda B; Chang SL; Kibel AS; Sun M; Trinh QD
Urol Oncol; 2014 Nov; 32(8):1333-40. PubMed ID: 25153773
[TBL] [Abstract][Full Text] [Related]
31. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
32. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
[TBL] [Abstract][Full Text] [Related]
33. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
34. Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study.
Kerleau C; Guizard AV; Daubisse-Marliac L; Heutte N; Mercier M; Grosclaude P; Joly F;
Eur J Cancer; 2016 Aug; 63():143-53. PubMed ID: 27318002
[TBL] [Abstract][Full Text] [Related]
35. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.
Lee JY; Cho KS; Kwon JK; Jeh SU; Kang HW; Diaz RR; Ham WS; Koom WS; Keum KC; Choi YD
Ann Surg Oncol; 2014 Nov; 21(12):4026-33. PubMed ID: 24841351
[TBL] [Abstract][Full Text] [Related]
36. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.
Lardas M; Liew M; van den Bergh RC; De Santis M; Bellmunt J; Van den Broeck T; Cornford P; Cumberbatch MG; Fossati N; Gross T; Henry AM; Bolla M; Briers E; Joniau S; Lam TB; Mason MD; Mottet N; van der Poel HG; Rouvière O; Schoots IG; Wiegel T; Willemse PM; Yuan CY; Bourke L
Eur Urol; 2017 Dec; 72(6):869-885. PubMed ID: 28757301
[TBL] [Abstract][Full Text] [Related]
37. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
38. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial.
Bill-Axelson A; Garmo H; Holmberg L; Johansson JE; Adami HO; Steineck G; Johansson E; Rider JR
Eur Urol; 2013 Dec; 64(6):920-8. PubMed ID: 23465517
[TBL] [Abstract][Full Text] [Related]
39. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]